Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Rankings
Industries / Tags:
Detailed Alexandria Venture Investments Information
Geographic Data
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$5B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2021 | SeQure DX | Series A | 0 |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 7/2021 | Wugen | Series B | 0 |
| 1/2019 | Frequency Therapeutics | Series B | - |
| 1/2021 | Encodia | Series C | 75M |
| 9/2022 | Novome | Series B | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 9/2018 | Epic Sciences | Series E | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 10/2019 | Molecular Assemblies | Series A | 0 |
| 1/2019 | Immusoft | Series B | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 3/2022 | Umaro Foods | Seed Round | 0 |
| 1/2020 | TwinStrand Biosciences | Series A | 16M |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 3/2022 | Eclipse Bioinnovations | Series A | 14M |
| 8/2021 | Humacyte | PIPE | 175M |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 10/2021 | Immunai | Series B | 215M |
| 10/2021 | Crop Enhancement | Convertible Note | - |
| 5/2021 | Inari | Series D | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 9/2021 | Kytopen | Series A | 0 |
| 3/2019 | Cardea Bio | Series A | 7.8M |
| 6/2021 | TRex Bio | Series A | 59M |
| 5/2021 | Invaio Sciences | Series C | 88.9M |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 9/2020 | Korro Bio | Series A | 0 |
| 4/2023 | Function Oncology | Series A | 28M |
| 9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 12/2018 | Kallyope | Series B | 21M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 8/2018 | Inari | Series B | 40M |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 2/2022 | Harpe Bio | Venture Round | 3M |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 2/2022 | Harpe Bio | Convertible Note | 3.2M |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 12/2020 | Faze Medicines | Series A | 81M |
| 7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 3/2019 | Gencove | Seed Round | 3M |
| 7/2021 | Deep Genomics | Series C | 0 |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 3/2017 | EGenesis | Series A | 0 |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 3/2020 | Kallyope | Series C | 112M |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 12/2022 | SonoThera | Series A | 0 |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 10/2017 | Visterra | Series C | 0 |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 7/2021 | IgGenix | Series A | 0 |
| 6/2018 | StrideBio | Series A | 15.7M |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 12/2019 | Jasper Therapeutics | Series A | 35M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 7/2017 | Evelo Biosciences | Series B | 50M |
| 10/2017 | Cydan | Venture Round | 34M |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 9/2018 | OncoResponse | Series B | 40M |
| 9/2018 | MouSensor | Seed Round | 3.3M |
| 3/2022 | Creyon Bio | Series A | 0 |
| 2/2019 | Applied Therapeutics | Series B | 0 |
| 6/2020 | Element Biosciences | Series B | 30M |
| 10/2019 | Verseau Therapeutics | Equity | 50M |
| 1/2021 | AltPep | Series A | 23.1M |
| 6/2023 | AltPep | Series B | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 11/2019 | Genetron Health | Series D | 71M |
| 1/2017 | Halio | Series C | 65M |
| 4/2018 | QurAlis | Seed Round | - |
| 9/2018 | ENB Therapeutics | Series A | 8.1M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 11/2019 | miRecule | Seed Round | 0 |
| 1/2023 | Melonfrost | Seed Round | 7M |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 2/2017 | Applied Therapeutics | Series A | 6.1M |
| 5/2021 | Marvin | Seed Round | 0 |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 5/2021 | miRecule | Venture Round | 0 |
| 10/2021 | Soli Organic | Venture Round | 0 |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 1/2019 | Greenlight Biosciences | Venture Round | 50M |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 10/2021 | DNA Script | Series C | 0 |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 11/2018 | Ribometrix | Series A | 30M |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 6/2018 | Cibus | Series C | 70M |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 4/2019 | Insitro | Series A | 100M |
| 9/2021 | Disc Medicine | Series B | 90M |
| 2/2021 | Ensoma | Series A | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 7/2018 | ORIG3N | Series B | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 1/2021 | Blacksmith Medicines | Seed Round | - |
| 10/2020 | Dren Bio | Series A | 0 |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 5/2021 | Advanced Animal Diagnostics | Series E | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 3/2021 | StrideBio | Series B | 0 |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 3/2022 | TRex Bio | Series A | 0 |
| 3/2018 | TCR2 | Series B | 0 |
| 2/2022 | Kallyope | Series D | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 2/2018 | Quentis | Series A | 48M |
| 1/2022 | Korro Bio | Series B | 0 |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 12/2021 | NextVivo | Venture Round | 7.9M |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 3/2020 | Affinia Therapeutics | Series A | 0 |
| 12/2022 | Dantari | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 9/2018 | Benson Hill | Series C | 65M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
| 2/2022 | Terray Therapeutics | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 11/2022 | Rezo | Series A | 0 |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 1/2021 | Vera Therapeutics | Series C | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2018 | System1 Biosciences | Series A | 25M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 2/2018 | Kallyope | Series B | 66M |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 7/2020 | Vesigen Therapeutics | Series A | 28.5M |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 9/2021 | Acrigen Biosciences | Seed Round | - |
| 10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 1/2022 | Avalo | Convertible Note | 750k |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 4/2021 | Alloy Therapeutics | Series C | 75M |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
